Company intelligence / Profile preview
Suzhou Fundamenta Therapeutics
Suzhou, Jiangsu, Chinafundamentatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Fundamenta Therapeutics is advancing allogeneic CAR-T therapies targeting hematologic malignancies and autoimmune diseases. Lead programs are in early clinical development with promising transition rates for their indications. No late-stage or commercialized products as of May 2025.
- Therapeutic areas
- OncologyHematology
- Modalities
- Allogeneic CAR-T cell therapyTCR therapyMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaboration with Zhejiang University on ThisCART19A program
Beyond the preview
Go deeper on Suzhou Fundamenta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Fundamenta Therapeutics.